Your browser doesn't support javascript.
loading
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis.
Tubau-Juni, Nuria; Hontecillas, Raquel; Leber, Andrew; Maturavongsadit, Panita; Chauhan, Jyoti; Bassaganya-Riera, Josep.
Affiliation
  • Tubau-Juni N; Landos Biopharma, Inc., Blacksburg, VA, 24060, USA.
  • Hontecillas R; Landos Biopharma, Inc., Blacksburg, VA, 24060, USA.
  • Leber A; Landos Biopharma, Inc., Blacksburg, VA, 24060, USA.
  • Maturavongsadit P; Landos Biopharma, Inc., Blacksburg, VA, 24060, USA.
  • Chauhan J; Landos Biopharma, Inc., Blacksburg, VA, 24060, USA.
  • Bassaganya-Riera J; Landos Biopharma, Inc., Blacksburg, VA, 24060, USA. jbr@landosbiopharma.com.
Sci Rep ; 11(1): 19827, 2021 10 06.
Article in En | MEDLINE | ID: mdl-34615968

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Signal Transduction / Phosphate-Binding Proteins / Immunosuppressive Agents / Membrane Proteins / Anti-Inflammatory Agents Type of study: Etiology_studies Limits: Animals Language: En Journal: Sci Rep Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Signal Transduction / Phosphate-Binding Proteins / Immunosuppressive Agents / Membrane Proteins / Anti-Inflammatory Agents Type of study: Etiology_studies Limits: Animals Language: En Journal: Sci Rep Year: 2021 Type: Article Affiliation country: United States